Abstract:Understanding transporter-mediated drug–drug interactions (DDIs) for investigational agents is important during drug development to assess DDI liability, its clinical relevance, and to determine appropriate DDI management strategies. P-glycoprotein (P-gp) is an efflux transporter that influences the pharmacokinetics (PK) of various compounds. Assessing transporter induction in vitro is challenging and is not always predictive of in vivo effects, and hence there is a need to consider clinical DDI studies; however, there is no clear guidance on when clinical evaluation of transporter induction is required. Furthermore, there is no proposed list of index transporter inducers to be used in clinical studies. This review evaluated DDI studies with known P-gp inducers to better understand the mechanism and site of P-gp induction, as well as the magnitude of induction effect on the exposure of P-gp substrates. Our review indicates that P-gp and cytochrome P450 (CYP450) enzymes are co-regulated via the pregnane xenobiotic receptor (PXR) and the constitutive androstane receptor (CAR). The magnitude of the decrease in substrate drug exposure by P-gp induction is generally less than that of CYP3A. Most P-gp inducers reduced total bioavailability with a minor impact on renal clearance, despite known expression of P-gp at the apical membrane of the kidney proximal tubules. Rifampin is the most potent P-gp inducer, resulting in an average reduction in substrate exposure ranging between 20 and 67%. For other inducers, the reduction in P-gp substrate exposure ranged from 12 to 42%. A lower reduction in exposure of the P-gp substrate was observed with a lower dose of the inducer and/or if the administration of the inducer and substrate was simultaneous, i.e. not staggered. These findings suggest that clinical evaluation of the impact of P-gp inducers on the PK of investigational agents that are substrates for P-gp might be warranted only for compounds with a relatively steep exposure–efficacy relationship.

Evaluation of Drug Interactions with P-Glycoprotein in Drug Discovery: In Vitro Assessment of the Potential for Drug-Drug Interactions with P-Glycoprotein

The Effects of Traditional Chinese Medicine on P-Glycoprotein–Mediated Multidrug Resistance and Approaches for Studying the Herb–P-Glycoprotein Interactions

Drug-drug interactions mediated by p-glycoprotein

On Interactions of P-glycoprotein with Various Anti-Tumor Drugs by Binding Free Energy Calculations

Research Progress on P-glycoprotein-mediated Drug Interactions

Effects of P-glycoprotein on the Pharmacokinetics and Interaction Mediated by P-glycoprotein

Role of P-glycoprotein in drug disposition

Rapid identification of P-glycoprotein substrates and inhibitors

Functional interactions between P-glycoprotein and CYP3A in drug metabolism

Progress in Search for Interactions Between P-glycoprotein and Central Depressants

Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery

Research progress of P-glycoprotein induction

Computationally accelerated identification of P-glycoprotein inhibitors

Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies

Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: A comprehensive review

P-glycoprotein Mediated Drug-Drug Interaction of Central Nervous System Drugs

Reliability of in Vitro and in Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain

Recent developments of P-glycoprotein inhibitors and its structure-activity relationship (SAR) studies

Comparing Various in Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P‐glycoprotein (p‐gp) Transporter in Vivo

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics